Fusen Pharmaceutical Company Limited (01652) issued a monthly return for the period ended November 30, 2025. The announcement shows that the company’s total authorized share capital remained at 2,000,000,000 ordinary shares, each with a par value of HKD 0.01, translating into HKD 20,000,000 in authorized share capital.

The number of issued shares stood at 739,301,000, consistent with the previous month, and the company reported no treasury shares. Under a share option scheme adopted on June 14, 2018, 16,000,000 share options remain outstanding at an exercise price of HKD 3.098 per share, with no options exercised during the month. The announcement confirms compliance with relevant listing and regulatory requirements.